Rigel(US:RIGL) Prnewswire·2026-01-12 13:05Core Insights - Rigel Pharmaceuticals reported strong financial performance in 2025, with record net product sales and significant cash generation, anticipating continued growth in 2026 [2][4][11] Financial Performance - Preliminary total revenue for Q4 2025 is expected to be approximately $69.8 million, a 21% increase from $57.6 million in Q4 2024 [5] - For the full year 2025, total revenue is projected to be $294.3 million, up from $179.3 million in 2024, representing a growth of 64% [5] - Net product sales for 2025 are expected to be $232.0 million, a 60% increase compared to 2024 [7] Product Sales Breakdown - Q4 2025 net product sales include: - TAVALISSE: $45.6 million, up from $31.0 million in Q4 2024 - GAVRETO: $10.2 million, up from $8.1 million in Q4 2024 - REZLIDHIA: $9.6 million, up from $7.4 million in Q4 2024 [5] Clinical Development - Rigel is advancing its Phase 1b clinical study of R289 for lower-risk MDS, with preliminary data indicating 33% of patients achieved red blood cell transfusion independence [9] - The company plans to complete enrollment in the dose expansion phase of the R289 study by the second half of 2026 and share preliminary results by the end of 2026 [9][11] 2026 Outlook - Rigel anticipates total revenue for 2026 to be between $275 million and $290 million, with net product sales projected at $255 million to $265 million [11] - The company expects to report positive net income for the full year 2026 while funding existing and new clinical development programs [11]